• Phare
  • Validé par KD/KO

Anticorps Polyclonal de lapin anti-TDP-43 (C-terminal)

TDP-43 (C-terminal) Polyclonal Antibody for WB, IHC, IF/ICC, IF-Fro, FC (Intra), IP, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris

Applications

WB, IHC, IF/ICC, IF-Fro, FC (Intra), IP, ELISA

Conjugaison

Non conjugué

N° de cat : 12892-1-PBS

Synonymes

TARDBP, TDP 43, TDP43, TDP-43, ALS10



Informations sur le produit

12892-1-PBS cible TDP-43 (C-terminal) dans les applications de WB, IHC, IF/ICC, IF-Fro, FC (Intra), IP, ELISA et montre une réactivité avec des échantillons Humain, rat, souris

Réactivité Humain, rat, souris
Hôte / Isotype Lapin / IgG
Clonalité Polyclonal
Type Anticorps
Immunogène Protéine recombinante
Nom complet TAR DNA binding protein
Masse moléculaire calculée 43 kDa
Poids moléculaire observé 43-45 kDa, 35 kDa
Numéro d’acquisition GenBankBC001487
Symbole du gène TDP-43
Identification du gène (NCBI) 23435
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par affinité contre l'antigène
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

Transactivation response (TAR), DNA-binding protein of 43 kDa (also known as TARDBP or TDP-43), was first isolated as a transcriptional inactivator binding to the TAR DNA element of the HIV-1 virus. Neumann et al. (2006) found that a hyperphosphorylated, ubiquitinated, and cleaved form of TARDBP, known as pathologic TDP-43, is the major component of the tau-negative and ubiquitin-positive inclusions that characterize amyotrophic lateral sclerosis (ALS) and the most common pathological subtype of frontotemporal lobar degeneration (FTLD-U). 12892-1-AP is a rabbit polyclonal antibody raised against the C-terminal amino acids of human TDP-43. This antibody recognizes the cleavage product of 20-30 kDa in addition to the native and phosphorylated forms of TDP-43. Immunohistochemical analyses of TDP-43 using this antibody detect both normal diffuse nuclear staining and insoluble inclusions in pathologic tissues. Various forms of TDP-43 exist, including 18-35 kDa of cleaved C-terminal fragments, 45-50 kDa phosphoprotein, 55 kDa glycosylated form, 75 kDa hyperphosphorylated form, and 90-300 kDa cross-linked form. (17023659,19823856,21666678,22193176)

Recently TDP-43 has been reported to be overexpressed in triple negative breast cancer (TNBC) and it may be a potential target for TNBC diagnosis and drug design. (29581274)

{{ptg:RelatedPrimaryAntibodies}}